Volume 9, Number 8—August 2003
Fluid Intake and Decreased Risk for Hospitalization for Dengue Fever, Nicaragua
In a hospital and health center-based study in Nicaragua, fluid intake during the 24 hours before being seen by a clinician was statistically associated with decreased risk for hospitalization of dengue fever patients. Similar results were obtained for children <15 years of age and older adolescents and adults in independent analyses.
Dengue fever (DF) and dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) are major public health problems worldwide (1). In addition to causing considerable illness and death, dengue epidemics also have a major economic impact, attributable primarily to the cost of medical care, plus vector control programs and lost productivity (2,3). DF and DHF/DSS are indistinguishable in the initial febrile phase, and few reliable clinical prognostic indicators of DHF/DSS exist (4). Near the time of defervescence, the plasma leakage syndrome of DHF/DSS can develop suddenly and be fatal if not managed properly. As a result, in areas relatively new to dengue, such as Latin America where DF and DHF/DSS have been spreading over the last 2 decades, high hospitalization rates for DF can occur because of the fear of discharging a patient whose case may progress to DHF/DSS. As DHF/DSS becomes hyperendemic, as in Southeast Asia, and extensive experience is garnered in case management, most hospitalizations for dengue are due to frank DHF/DSS. We conducted a study to assess the extent of hospitalization attributable to dengue in Nicaragua and to examine the role of factors such as prior fluid intake on the risk for hospitalization.
Participating hospitals and health centers in urban centers of the Pacific region of Nicaragua included the Hospital Escuela Oscar Danilo Rosales Argüello in León, the pediatric reference Hospital Infantil Manuel de Jesus Rivera in Managua, and four health centers in Managua, which serve a combined population of 1.95 million people. A cross-sectional study of 2,820 suspected dengue cases was conducted from January 1 to December 31, 1999. Enrollment criteria consisted of acute febrile illness accompanied by two or more of the following symptoms of DF: fever, severe headache, retroorbital pain, myalgias, arthralgias, and rash (4,5). A standardized questionnaire was used to collect demographic and clinical information, including ingestion of fluids in the 24 hours before first being seen by a clinician, as reported by the patient or parent. Of the 1,312 patients who tested positive for DENV infection, the mean age was 15.3 years (range 0–85), and 557 (42%) were male (Table 1). Venous blood was drawn at the first visit, and convalescent-phase serum specimens were obtained when possible (19% of patients). Clinical evolution of the illness among hospitalized patients was documented by chart review with standardized data-entry forms. This study was approved by the Institutional Review Boards of both University of California, Berkeley (#99-4-38) and the Centro Nacional de Diagnóstico y Referencia of the Nicaraguan Ministry of Health (#99-04).
Dengue virus (DENV) infection was identified in 1,312 patients by serologic methods (immunoglobulin M-capture enzyme-linked immunosorbent assay [ELISA] or inhibition ELISA for total anti-DENV antibodies), virologic means (virus isolation, reverse transcriptase-polymerase chain reaction), or both (5). DENV2, DENV4, and DENV3 accounted for 79%, 17%, and 5% of the typed viruses, respectively. Dengue fever was divided into classic DF and DF with hemorrhagic manifestations (DFHem); severe dengue was defined as DHF (World Health Organization classification DHF grades I and II), DSS (World Health Organization DHF grades III and IV) (1), or an additional classification designated “dengue with signs associated with shock” (DSAS). DSAS was designated when either hypotension for age or narrow pulse pressure plus clinical signs of shock were present and serial hematocrit and platelet counts failed to document thrombocytopenia and hemoconcentration, potentially attributable to fluid replacement therapy (5). The relationship between hospitalization and fluid intake was assessed by unconditional logistic regression. Because virtually every patient with severe dengue was hospitalized, such risk factor analysis was not suitable for these patients as a separate group. Thus, the analysis was restricted to DF and DFHem patients. Univariate and multivariate analyses were performed separately on children (<15 years of age) and older adolescents and adults (>15 years of age). Covariates found to be significant in univariate analyses were included in the initial multivariate models (Table 2).
Although a much higher proportion of severe dengue patients were hospitalized compared with DF and DFHem patients, larger absolute numbers of hospitalizations were due to classic DF and DFHem because many more cases of DF/DFHem than of severe dengue occur (Table 1). Thus, of all the laboratory-confirmed DENV-positive hospitalized patients, classic DF (23.5%) and DFHem (50.0%) cases comprised three times as many as DHF, DSS, and DSAS combined (23.6%). These profiles have been maintained from year to year, with 28% and 20% of hospitalized cases due to classic DF and 51% and 58% due to DFHem in 1998 and 2000, respectively (5). Furthermore, the mean duration of hospitalization was similar for patients with DF and those with severe dengue (Table 1).
Among children with DF or DFHem, ingestion of fluid in the 24 hours before being seen by a clinician was found to be protective against hospitalization after adjusting for distance from health facility, date of symptom onset, and thrombocytopenia (odds ratio [OR]=0.74 per each additional glass consumed, 95% confidence intervals [CI] 0.66 to 0.83, p<0.01) (Table 2). Similar results were obtained for older adolescents and adults after adjusting for date of symptom onset and thrombocytopenia, with an OR of 0.71 (95% CI 0.59 to 0.85, p<0.01). In analyses with a statistical model that did not assume a linear relationship between number of glasses ingested and hospitalization, additional benefit was noted for each glass up to five, after which the incremental benefit remained constant. Thus, in a model that compared the fluid intake of five glasses or less than five glasses with ingestion of more than five glasses, the adjusted OR for hospitalization was 0.19 (95% CI 0.09 to 0.39, p<0.01) among DF and DFHem cases in children and 0.20 (95% CI 0.07 to 0.57, p<0.01) in those >15 years of age (Table 2). We also performed the analysis with all disease states, including severe dengue cases, and the results were virtually identical to those obtained with only DF/DFHem cases (data not shown).
The most common liquid ingested was water (70%), followed by fruit juice (42%), lemonade (27%), milk (25%), coffee (14%), oral dehydration serum (6%), and tea (2%). The mean number of glasses ingested by nonhospitalized DF/DFHem case-patients was 5.2, whereas the mean number glasses ingested by hospitalized DF/DFHem patients was 2.8, similar to the mean of 2.9 glasses ingested by hospitalized severe patients (DHF/DSS/DSAS). These findings suggest that maintaining hydration may lead to reduced hospitalizations of patients with DF/DFHem. Other independent risk factors for hospitalization included in the final multivariate model were increasing distance from the healthcare facility, later date of symptom onset, and the presence of thrombocytopenia. The risk conferred by later date of symptom onset reflects increased awareness of dengue by medical staff as the annual epidemic intensified. Because thrombocytopenia is an indication for hospitalization (especially for pediatric dengue patients), its emergence as a risk factor is not surprising.
Because inpatient medical care of DF and DFHem patients can contribute significantly to the economic impact of dengue, we sought to define outpatient measures that could decrease DF hospitalization rates. Dengue patients are likely to be susceptible to dehydration because of high fever and concomitant anorexia. While oral rehydration therapy is listed as standard outpatient management for DHF (1), little discussion exists on the use of such therapy for DF and DFHem cases (4), and no published studies have examined the effect of fluid intake at home. Our results show that this simple measure may have a significant protective effect against hospitalization and potentially on the severity of DF/DFHem, although causality cannot be confirmed because of the observational nature of this study. To definitively demonstrate this effect, this question must be investigated by prospective intervention studies. However, our data do suggest that promoting a high fluid intake at home could help reduce the need for hospitalization and thus attenuate economic impact of dengue in countries experiencing epidemics of dengue fever.
Dr. Harris is an assistant professor in the Division of Infectious Diseases in the School of Public Health at the University of California, Berkeley, where her research program focuses on the pathogenesis and epidemiology of dengue virus. Over the past 8 years, she has collaborated with scientists at the Nicaraguan Ministry of Health to strengthen dengue surveillance and investigate the epidemiology of dengue in Nicaragua.
We are grateful to the hospital and health center staff, personnel in the Centro Nacional de Diagnóstico y Referencia virology laboratory, and the persons who participated in the study. We thank Art Reingold, Albert Ko, Scott Halstead, Michael Diamond, and Laurel Imhoff for helpful discussions or editorial comments.
This work was supported by grant #TW-00905 from the Fogarty International Center, National Institutes of Health.
- World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed. Geneva: The Organization; 1997.
- Von Allmen SD, Lopez-Correa RH, Woodall JP, Morens DM, Chiribiga J, Casta-Velez A. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am J Trop Med Hyg. 1979;28:1040–4.
- Ferrando JE. Estimate of the costs of the dengue epidemic in 1994 in Nicaragua. Pan American Health Organization Consultancy Report. OPS/HCP/HCT/95.64. Washington, DC: Pan American Health Organization;1995.
- Pan American Health Organization. Dengue and dengue hemorrhagic fever in the Americas: guidelines for prevention and control. Scientific pub. no. 548. 1994. Washington, DC: The Organization; 1994.
- Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg. 2000;63:5–11.
- Table 1. Characteristics of all hospitalized and unhospitalized dengue patientsa
- Table 2. Crude and adjusted odds ratios and 95% confidence intervals for factors potentially associated with hospitalization for classic dengue fever or dengue fever with hemorrhagic manifestations
Suggested citation for this article: Harris E, Pérez L, Phares DR, de los Angeles Pérez M, Idiaquez W, Rocha J, et al. Fluid intake and decreased risk for hospitalization for dengue fever, Nicaragua. Emerg Infect Dis [serial online] 2003 Aug [date cited]. Available from: URL: http://wwwnc.cdc.gov/eid/article/9/8/02-0456
Please use the form below to submit correspondence to the authors or contact them at the following address:
Eva Harris, Division of Infectious Diseases, School of Public Health, University of California, Berkeley, 140 Warren Hall, Berkeley, CA 94720-6350, USA; Fax: (510) 642-6350
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 22, 2010
- Page last updated: December 22, 2010
- Page last reviewed: December 22, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)